Yassin Belahnech, Eduard Ródenas-Alesina, Miguel Ángel Muñoz, Jose María Verdu-Rotellar, Augusto Sao-Avilés, Garazi Urio-Garmendia, Dimelza Osorio, Karla Salas, Efrain Pantoja, Aida Ribera, Ignacio Ferreira-González
{"title":"Systematic Coronary Risk Evaluation 2 for Older Persons (SCORE2-OP): 10 years risk validation, clinical utility and potential improvement.","authors":"Yassin Belahnech, Eduard Ródenas-Alesina, Miguel Ángel Muñoz, Jose María Verdu-Rotellar, Augusto Sao-Avilés, Garazi Urio-Garmendia, Dimelza Osorio, Karla Salas, Efrain Pantoja, Aida Ribera, Ignacio Ferreira-González","doi":"10.1093/eurjpc/zwae383","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>European Systematic Coronary Risk Assessment 2 for Older Persons (SCORE2-OP) model has shown modest performance when externally validated in selected cohorts. We aim to investigate its predictive performance and clinical utility for 10-years cardiovascular (CV) risk in an unbiased and representative cohort of older people of a low CV risk country. Furthermore, we explore whether other clinical or echocardiographic features could improve its performance.</p><p><strong>Methods and results: </strong>A cohort of randomly selected individuals ≥ 65 years from a primary care population of Barcelona without established cardiovascular disease included 791 patients (63.1% female, median age 76 years, median follow-up 11.8 years). The model's performance yielded a Harrell's C-statistic of 0.706 (95% CI 0.659-0.753) for the primary endpoint (myocardial infarction, stroke, cardiovascular mortality) and 0.692 (95% CI 0.649-0.734) for the secondary endpoint (primary endpoint plus heart failure hospitalization), with better discrimination in females. SCORE2-OP underestimated the risk of primary endpoint in women (Expected[E]/Observed[O]=0.77), slightly overestimated in men (E/O=1.06), and systematically underestimated the risk of the secondary endpoint (E/O=0.52). Decision curve analysis showed net clinical benefit across a 7.5-30% risk range for primary endpoint. Valvular calcification was the only variable that significantly improved 10-year SCORE2-OP risk performance for both primary and secondary endpoints, with a change in Harrell's C of 0.028 (P=0.017).</p><p><strong>Conclusion: </strong>In a low CV risk country, SCORE2-OP showed notable discrimination and excellent calibration to predict 10-year cardiovascular risk, with better performance in females. Incorporating valvular calcification in a future revised score may enhance accuracy and reduce unnecessary treatments.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4000,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of preventive cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/eurjpc/zwae383","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Aims: European Systematic Coronary Risk Assessment 2 for Older Persons (SCORE2-OP) model has shown modest performance when externally validated in selected cohorts. We aim to investigate its predictive performance and clinical utility for 10-years cardiovascular (CV) risk in an unbiased and representative cohort of older people of a low CV risk country. Furthermore, we explore whether other clinical or echocardiographic features could improve its performance.
Methods and results: A cohort of randomly selected individuals ≥ 65 years from a primary care population of Barcelona without established cardiovascular disease included 791 patients (63.1% female, median age 76 years, median follow-up 11.8 years). The model's performance yielded a Harrell's C-statistic of 0.706 (95% CI 0.659-0.753) for the primary endpoint (myocardial infarction, stroke, cardiovascular mortality) and 0.692 (95% CI 0.649-0.734) for the secondary endpoint (primary endpoint plus heart failure hospitalization), with better discrimination in females. SCORE2-OP underestimated the risk of primary endpoint in women (Expected[E]/Observed[O]=0.77), slightly overestimated in men (E/O=1.06), and systematically underestimated the risk of the secondary endpoint (E/O=0.52). Decision curve analysis showed net clinical benefit across a 7.5-30% risk range for primary endpoint. Valvular calcification was the only variable that significantly improved 10-year SCORE2-OP risk performance for both primary and secondary endpoints, with a change in Harrell's C of 0.028 (P=0.017).
Conclusion: In a low CV risk country, SCORE2-OP showed notable discrimination and excellent calibration to predict 10-year cardiovascular risk, with better performance in females. Incorporating valvular calcification in a future revised score may enhance accuracy and reduce unnecessary treatments.
期刊介绍:
European Journal of Preventive Cardiology (EJPC) is an official journal of the European Society of Cardiology (ESC) and the European Association of Preventive Cardiology (EAPC). The journal covers a wide range of scientific, clinical, and public health disciplines related to cardiovascular disease prevention, risk factor management, cardiovascular rehabilitation, population science and public health, and exercise physiology. The categories covered by the journal include classical risk factors and treatment, lifestyle risk factors, non-modifiable cardiovascular risk factors, cardiovascular conditions, concomitant pathological conditions, sport cardiology, diagnostic tests, care settings, epidemiology, pharmacology and pharmacotherapy, machine learning, and artificial intelligence.